U.S. markets closed
  • S&P Futures

    3,726.00
    -6.00 (-0.16%)
     
  • Dow Futures

    29,706.00
    -44.00 (-0.15%)
     
  • Nasdaq Futures

    11,526.00
    -29.75 (-0.26%)
     
  • Russell 2000 Futures

    1,718.70
    -2.10 (-0.12%)
     
  • Crude Oil

    82.24
    +0.09 (+0.11%)
     
  • Gold

    1,664.00
    -6.00 (-0.36%)
     
  • Silver

    18.77
    -0.10 (-0.56%)
     
  • EUR/USD

    0.9684
    -0.0055 (-0.56%)
     
  • 10-Yr Bond

    3.7050
    -0.2590 (-6.53%)
     
  • Vix

    30.18
    -2.42 (-7.42%)
     
  • GBP/USD

    1.0803
    -0.0083 (-0.76%)
     
  • USD/JPY

    144.2380
    +0.1160 (+0.08%)
     
  • BTC-USD

    19,373.70
    +411.40 (+2.17%)
     
  • CMC Crypto 200

    443.47
    +14.69 (+3.43%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,428.58
    +254.60 (+0.97%)
     

What Type Of Shareholders Make Up Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) Share Registry?

·4 min read

The big shareholder groups in Avalo Therapeutics, Inc. (NASDAQ:AVTX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.

Avalo Therapeutics is not a large company by global standards. It has a market capitalization of US$202m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about Avalo Therapeutics.

View our latest analysis for Avalo Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Avalo Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Avalo Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Avalo Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

It looks like hedge funds own 61% of Avalo Therapeutics shares. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Looking at our data, we can see that the largest shareholder is Armistice Capital LLC with 49% of shares outstanding. Nantahala Capital Management, LLC is the second largest shareholder owning 6.2% of common stock, and Point72 Asset Management, L.P. holds about 5.4% of the company stock.

To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Avalo Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our data suggests that insiders own under 1% of Avalo Therapeutics, Inc. in their own names. But they may have an indirect interest through a corporate structure that we haven't picked up on. It appears that the board holds about US$1.8m worth of stock. This compares to a market capitalization of US$202m. We generally like to see a board more invested. However it might be worth checking if those insiders have been buying.

General Public Ownership

The general public, who are usually individual investors, hold a 15% stake in Avalo Therapeutics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Company Ownership

Our data indicates that Private Companies hold 3.1%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 4 warning signs for Avalo Therapeutics you should be aware of, and 1 of them is significant.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.